Trastuzumab deruxtecan (Enhertu, Daiichi Sankyo) is indicated for 'the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy'.
The dosage schedule is available in the summary of product characteristics for trastuzumab deruxtecan.
The list price of trastuzumab deruxtecan is £1,455 per 1 vial containing 100 mg powder for concentrate for solution for infusion (excluding VAT; BNF online accessed June 2024).
The company has a commercial arrangement. This makes trastuzumab deruxtecan available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence.